Press Releases

10.01.2026

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

09.28.2026

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

09.22.2026

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

09.15.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.08.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

08.27.2026

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

08.14.2026

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

08.04.2026

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

07.30.2026

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

07.29.2026

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

07.22.2026

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

07.10.2026

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility